2023 FUTURES: RNA targeted Therapeutics Sessions Part 2

Continued updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

Jane Larkindale, DPhil

VP of Clinical Science PepGen

Dania Porco, MS, MBA, CGC

Director in Clinical Science BioMarin Pharmaceutical Inc.

Michael Tillinger, MD

VP of Clinical Development Wave Life Sciences

Related Resources

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.